PDF(Pubmed)
Abstract：
The growing research interest in the relationship between health insurance and pharmaceutical innovation is driven by their significant impact on healthcare optimization and pharmaceutical development. The existing literature, however, lacks consensus on this relationship and provides no evidence of the magnitude of a correlation. In this context, this study employs meta-analysis to explore the extent to which health insurance affects pharmaceutical innovation. It analyzes 202 observations from 14 independent research samples, using the regression coefficient of health insurance on pharmaceutical innovation as the effect size. The results reveal that there is a strong positive correlation between health insurance and pharmaceutical innovation (r = 0.367, 95% CI = [0.294, 0.436]). Public health insurance exhibits a stronger promoting effect on pharmaceutical innovation than commercial health insurance. The relationship between health insurance and pharmaceutical innovation is moderated by the country of sample origin, data range, journal type, journal impact factor, type of health insurance, and research perspective. Our research findings further elucidate the relationship mechanism between health insurance and pharmaceutical innovation, providing a valuable reference for future explorations in pharmaceutical fields.
摘要：
对健康保险和制药创新之间关系的研究兴趣日益增长，这是由它们对医疗保健优化和制药开发的重大影响所驱动的。现有文献,然而,在这种关系上缺乏共识，也没有提供相关程度的证据。在这种情况下，本研究采用荟萃分析来探讨医疗保险对药物创新的影响程度.它分析了来自14个独立研究样本的202个观察结果，以医疗保险对医药创新的回归系数为效应大小。结果表明，医疗保险与医药创新之间存在较强的正相关关系（r=0.367，95%CI=[0.294，0.436]）。公共健康保险对医药创新的促进作用强于商业健康保险。医疗保险与医药创新之间的关系受到样本来源国的调节，数据范围,日记帐类型,期刊影响因子，健康保险的类型，和研究视角。我们的研究结果进一步阐明了医疗保险与医药创新之间的关系机制。为今后医药领域的探索提供有价值的参考。
